Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong, China.
Cell Prolif. 2018 Aug;51(4):e12446. doi: 10.1111/cpr.12446. Epub 2018 Feb 27.
Accumulating evidence from genome-wide analysis and functional studies has begun to unveil the important role of long non-coding RNAs (lncRNAs) in cancer development. The lncRNA SPRY4-IT1 is derived from an intron of SPRY4 gene and was originally reported to be upregulated in melanoma in which it functioned as an oncogene. Since this discovery, an increasing number of studies have investigated the expression and function of SPRY4-IT1 in human cancers. Aberrant expression of SPRY4-IT1 has now been documented in different cancer types, including osteosarcoma, breast, renal, oesophageal and prostate cancers. However, its deregulation and function in lung and gastric cancers remain controversial. Pertinent to clinical practice, SPRY4-IT1 expression has been shown to predict survival of cancer patients. In this review, we summarize recent evidence concerning SPRY4-IT1 deregulation and the associated mechanisms in human cancers. We also discuss the potential clinical utilization of this lncRNA as a diagnostic and prognostic biomarker for cancer patients.
越来越多的全基因组分析和功能研究证据开始揭示长非编码 RNA（lncRNA）在癌症发展中的重要作用。lncRNA SPRY4-IT1 来源于 SPRY4 基因的内含子，最初报道其在黑色素瘤中上调，发挥癌基因的作用。自这一发现以来，越来越多的研究调查了 SPRY4-IT1 在人类癌症中的表达和功能。现已在不同类型的癌症中记录到 SPRY4-IT1 的异常表达，包括骨肉瘤、乳腺癌、肾癌、食管癌和前列腺癌。然而，其在肺癌和胃癌中的失调和功能仍存在争议。与临床实践相关的是，SPRY4-IT1 的表达已被证明可以预测癌症患者的生存。在这篇综述中，我们总结了最近关于 SPRY4-IT1 失调及其在人类癌症中相关机制的证据。我们还讨论了将这种 lncRNA 作为癌症患者的诊断和预后生物标志物的潜在临床应用。
